Enlicitide (Lipfendra) – An Oral PCSK9 Inhibitor for LDL-Cholesterol Lowering
View Full Paper
Ask AI
Bookmark
Share
Discussion
Loading...
Member takes
Overview
Regulatory review reports FDA approval of oral enlicitide for lowering LDL-cholesterol in adults with hypercholesterolemia, highlighting an oral alternative to injectable PCSK9-targeted therapies.
Key Points
Summarize the FDA approval and therapeutic profile of enlicitide (Lipfendra) as the first orally administered PCSK9 inhibitor for LDL-C reduction.
Evaluation of enlicitide for drug approval under the FDA Commissioner's National Priority Voucher program.
Regulatory indication assessment in adult populations with hypercholesterolemia and heterozygous familial hypercholesterolemia (HeFH).
Enlicitide received FDA approval to reduce LDL-C in adults with hypercholesterolemia, including HeFH.
The agent marks the first orally available PCSK9 inhibitor approved in the United States, contrasting with existing subcutaneous monoclonal antibodies and small interfering RNA therapies.